ArticleScientific reports2026
3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) is a potential diagnostic and prognostic biomarker in colon adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer represents a global health challenge. The 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is the universal sulfonate donor for all sulfation reactions. However, the correlation between PAPSS2 and diagnosis, prognosis, and immune cell infiltration in colon adenocarcinoma (COAD) has rarely been mentioned. We analyzed PAPSS2 expression levels in pan-cancer from The Cancer Genome Atlas (TCGA) database; and validated it in the Gene Expression Omnibus (GEO) database. RNA-seq data were analyzed using the R package to identify differentially expressed genes (DEGs) between COAD tissues with high and low PAPSS2 expression from multiple databases. The ssGSEA algorithm was used to analyze the correlation between PAPSS2 and immune cell infiltration in COAD. Tumor tissues and normal tissues were classified and assayed at the single-cell level to analyze differences in PAPSS2 expression. CCK8 and EdU assays were used to validate proliferative capacity; wound healing assays to validate migratory capacity; and Transwell assays to examine changes in invasive capacity. The PAPSS2 expression level was significantly lower in the tumor tissues and associated with worse clinical parameters and prognosis in COAD patients. And we constructed a transcriptional regulatory network involving FLI1 and hsa-miR-152-3p targeting PAPSS2 to support the role of PAPSS2.Enrichment analysis revealed that PAPSS2 is involved in O-glycan biosynthesis, TP53 pathway and extracellular matrix formation. PAPSS2 was found to be positively associated with the infiltration of numerous immune cells, immunomodulatory factors and chemokines. Cytological experiments demonstrated that PAPSS2 knockdown enhanced the proliferation, migration, and invasion of HCT116 and HT-29 cells. Our study suggests that PAPSS2 acts as a promising diagnostic and prognostic biomarker, which facilitates malignant progression in part through its regulation of the p53 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.